eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Suplementy Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
4/2024
vol. 11
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

Personalized biological treatment with lanadelumab in a patient with recurrent attacks of hereditary angioedema

Artur Gęsicki
1
,
Maciej F. Kozlowski
1
,
Karolina Żurawska
1
,
Weronika Ossowska
1
,
Jakub Sikora
1
,
Szymon Dyguś
1
,
Iwona Poziomkowska-Gęsicka
1

  1. Department of Clinical Allergology, Pomeranian Medical University, Szczecin, Poland
Alergologia Polska – Polish Journal of Allergology 2024; 11, 4: 332–334
Data publikacji online: 2024/08/29
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Hereditary angioedema (HAE) is an autosomal dominantly inherited disease caused by deficiency of C1 esterase inhibitor protein type 1 (about 85% of patients with HAE-C1-INH) or type 2 oedema (about 15% of patients with HAE-C1-INH) by C1 inhibitor dysfunction, with normal serum levels (HAE-2). Long-term treatment to prevent further attacks consists of continuous and regular administration of medications to reduce the number and severity of oedema attacks in HAE patients, thereby reducing the indirect burden of the disease. With the severe course of the disease, potentially life-threatening during flare-ups, it is expedient to implement long-term HAE attacks prophylaxis, which was very limited in Poland until September 2021.


© 2024 Termedia Sp. z o.o.
Developed by Bentus.